Logo do repositório
 
Publicação

Determination of essential biomarkers in lung cancer

2022-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorProvencio, Mariano
dc.contributor.authorCobo, Manuel
dc.contributor.authorRodriguez-Abreu, Delvys
dc.contributor.authorCalvo, Virginia
dc.contributor.authorCarcereny, Enric
dc.contributor.authorCantero, Alexandra
dc.contributor.authorBernabé, Reyes
dc.contributor.authorBenitez, Gretel
dc.contributor.authorCastro, Rafael López
dc.contributor.authorMassutí, Bartomeu
dc.contributor.authordel Barco, Edel
dc.contributor.authorGarcía Campelo, Rosario
dc.contributor.authorGuirado, Maria
dc.contributor.authorCamps, Carlos
dc.contributor.authorOrtega, Ana Laura
dc.contributor.authorGonzález Larriba, Jose Luis
dc.contributor.authorSánchez, Alfredo
dc.contributor.authorCasal, Joaquín
dc.contributor.authorSala, M. Angeles
dc.contributor.authorJuan-Vidal, Oscar
dc.contributor.authorBosch-Barrera, Joaquim
dc.contributor.authorOramas, Juana
dc.contributor.authorDómine, Manuel
dc.contributor.authorTrigo, Jose Manuel
dc.contributor.authorBlanco, Remei
dc.contributor.authorCalzas, Julia
dc.contributor.authorMorilla, Idoia
dc.contributor.authorPadilla, Airam
dc.contributor.authorPimentão, João
dc.contributor.authorSousa, Pedro A.
dc.contributor.authorTorrente, Maria
dc.contributor.institutionDEE - Departamento de Engenharia Electrotécnica e de Computadores
dc.contributor.pblBioMed Central (BMC)
dc.date.accessioned2022-12-09T22:14:37Z
dc.date.available2022-12-09T22:14:37Z
dc.date.issued2022-12
dc.descriptionFunding Information: This study was supported by the European Union Horizon 2020 Research and Innovation Program under grant agreement n° 875160 CLARIFY project. Funding Information: The authors thank all investigators who participated in the RRTT registry: Dr. Pilar Diaz (Complejo Asistencial Universitario de León, Spain), Dr. Rosa M. Villatoro (Hospital Costa del Sol, Marbella, Spain), Dr. Pilar Lianes (Hospital de Mataró, Barcelona, Spain), Dr. M. Rosario Hernández (Hospital Ntra. Sra Sonsoles, Ávila, Spain), Dr. Juana Oramas (Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain), Dr. Karmele Areses (Complejo Hospitalario e Ourense, Spain), Dr. Rafael Lopez (Hospital Clinico Universitario de Valladolid, Spain), Dr. Julio Ocaña (Hospital CIMA Sanitas, Barcelona, Spain), Dra. María Gonzalez Cao (Hospital Universario Quiron-Dexeus, Barcelona, Spain), Dr. Noemí Reguart (Hospital Clinic Barcelona, Spain), Dr. Manuel Fernández (Hospital HM la Esperanza, Santiago de Compostela, A Coruña, Spain), Dr. Luis Enrique Chara (Hospital Universitario de Guadalajara, Spain), Dr. Judit Rubio (Hospital Universitario de Móstoles, Madrid, Spain), Dr. Alfonso Gurpide (Clinica Universitaria de Navarra, Pamplona, Spain), Dr. Ana Reyes García (Hospital Universitario Río Hortega, Valladolid, Spain), Dr. Beatriz Esteban (Hospital General de Segovia, Spain). We also thank the patients, their families, all the participating clinical teams and the Spanish Lung Cancer Group for coordinating the study. M.P. contributed to the conception and design of the study. D.R.A., M.T., A.LO., C.C., V.C., M.D., G.B., A.P., A.C., R.B., R.G.C., E.C., B.M., J.B.B., O.J.V., M.C., E.d.B., R.L.C., J.L.G., A.S., M.G., R.L.C., J.C., J.O., M.A.S., J.M.T., R.B., J.C., and I.M. contributed to acquisition of study data. M.P. and M.T. contributed to data analysis and writing of the manuscript, J. P. and P.A.S. to the writing and revision. All authors had full access to all the data in the study and final responsibility for the decision to submit for publication. The author(s) read and approved the final manuscript. Publisher Copyright: © 2022, The Author(s).
dc.description.abstractBackground: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods: The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. Results: Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value < 0.001). The global testing of EGFR, ALK, and ROS1 was 78.9, 64.7, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or high PDL1. Conclusions: Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing (NGS) in an integrated and cost-effective way in lung cancer.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent11
dc.format.extent859423
dc.identifier.doi10.1186/s12885-022-09830-8
dc.identifier.issn1471-2407
dc.identifier.otherPURE: 45463480
dc.identifier.otherPURE UUID: 8eed423b-3aea-4ff8-a789-eeb1d0392c3d
dc.identifier.otherScopus: 85133407005
dc.identifier.otherPubMedCentral: PMC9254518
dc.identifier.otherPubMed: PMID: 35790916
dc.identifier.otherWOS: 000820999500002
dc.identifier.urihttp://hdl.handle.net/10362/146094
dc.identifier.urlhttps://www.scopus.com/pages/publications/85133407005
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBiomarkers
dc.subjectMetastatic lung cancer
dc.subjectTargeted therapies
dc.subjectTesting
dc.subjectOncology
dc.subjectGenetics
dc.subjectCancer Research
dc.subjectSDG 3 - Good Health and Well-being
dc.titleDetermination of essential biomarkers in lung canceren
dc.title.subtitlea real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristicsen
dc.typejournal article
degois.publication.issue1
degois.publication.titleBMC Cancer
degois.publication.volume22
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Determination_of_essential_biomarkers_in_lung_cancer_a_real_world_data_study_in_Spain_with_demographic_clinical_epidemiological_and_pathological_characteristics.pdf
Tamanho:
839.28 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (FCT)